Healthcare / Medical Care FacilitiesTokyo
$409.00
-2.00 (-0.49%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 13%
FCF escenarios
weak_data · normalized FCF $479.7M · quality 25.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.5B
P/E
14.4x
↓EV/EBITDA
7.8x
↓ROE
8.7%
↑Gross Margin
23.1%
↓Debt/Equity
4.19
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.8%
FCF CAGR
+116.3%
FCF margin
3.9%
FCF / Net income
4.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $48.16B · net income $384.2M · FCF $1.86B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $48.16B | $48.16B | $45.40B | $41.10B | $38.40B |
| Net Income | $384.2M | $384.2M | $278.4M | $6.2M | $630.5M |
| EBITDA | $2.54B | $2.54B | $2.20B | $2.33B | $3.12B |
| EPS | — | — | 20.64 | 0.46 | 46.83 |
| Gross Margin | 23.1% | 23.1% | 21.3% | 21.9% | 24.1% |
| Operating Margin | 1.6% | 1.6% | -1.0% | -1.0% | 2.9% |
| Net Margin | 0.8% | 0.8% | 0.6% | 0.0% | 1.6% |
| Balance Sheet | |||||
| Debt/Equity | 4.19 | 4.19 | 4.14 | 3.34 | 3.48 |
| Current Ratio | 1.16 | 1.16 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.86B | $1.86B | $-502.4M | $479.7M | $184.1M |
| Returns | |||||
| ROE | 8.7% | 8.7% | 5.9% | 0.1% | 9.8% |
| Valuation | |||||
| P/E | 14.37 | 14.37 | 19.38 | 1389.13 | 15.89 |
| EV/EBITDA | 7.85 | 7.85 | 9.90 | 10.44 | 9.81 |
| P/B | 1.25 | 1.25 | 1.15 | 1.57 | 1.55 |
| Growth & Yield | |||||
| Revenue Growth | 6.1% | 6.1% | 10.5% | 7.0% | — |
| EPS Growth | — | — | 4387.0% | -99.0% | — |
| Dividend Yield | 4.2% | 4.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.4%
Start / end P/E
n/dx → n/dx
EPS bridge
20.64 → n/d
Residual
+3.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.